News of Note—Médecins Sans Frontières, HIV vaccines and more
admin 28th November 2017 Uncategorised 0Here is some other vaccine news of note for the week. More: News of Note—Médecins Sans Frontières, HIV vaccines and more Source: fierce
read moreHere is some other vaccine news of note for the week. More: News of Note—Médecins Sans Frontières, HIV vaccines and more Source: fierce
read moreGlaxoSmithKline’s ViiV only just won its first two-drug HIV approval, but it’s already bolstering its trial program to see just how convenient it can make a two-drug regimen. More: Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV
read moreOver the years, as Pfizer’s Prevnar 13 has grown into the company’s biggest product and the world’s best-selling vaccine, its price tag has shot up considerably as well. Now, the superstar vaccine is set for another price hike in 2018,
read morePfizer and Merck KGaA are working to carve out a niche for immuno-oncology drug Bavencio in a crowded field. But a failed phase 3 trial in advanced stomach cancer just dinged their ambitions. More: Pfizer, Merck KGaA's Bavencio flops in
read moreEven after the Biomedical Advanced Research and Development Authority suspended funding to its Sanofi-partnered Zika vaccine project, the agency continued its financial commitment to Takeda’s project. Now, Takeda has advanced its candidate into human testing. More: Takeda pushes U.S.-backed Zika
read moreNew analysis highlights that Scotland’s pharmaceutical industry “can be a driving force” for long-term sustainable economic growth, says the Association of the British Pharmaceutical Industry Scotland. More: Scotland’s pharma industry ‘a driving force’ for economic growth Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals